Navigation Links
Epitomics Appoints Dr. Zhiqiang An as Chief Scientific Officer
Date:12/16/2008

BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr. An comes to Epitomics from Merck Research Laboratories, where he was Director of Biologics Research. He has over 12 years of experience in drug discovery and development in the biotech and pharmaceutical industries, focusing on therapeutic antibody discovery, humanization and affinity maturation, preclinical and clinical development.

Epitomics, exclusive maker of RabMAb(R) monoclonal antibodies, is the commercial supplier of rabbit monoclonal antibodies, with customers around the world, including major biotechnology/pharmaceutical companies and academic research laboratories. With several recently issued industry-changing patents, Epitomics has established its proprietary RabMAb as a unique antibody technology with an excellent IP position. The addition of Dr. An further sets the stage for Epitomics to move aggressively into the human antibody therapeutic market starting with major pre-clinical work on multiple targets in 2009.

"Dr. An brings a wealth of knowledge and experience in antibody discovery, which he will leverage with Epitomics' strong technologies and innovation to generate a pipeline of best-in-class antibody therapeutics focusing on clinically proven targets for broad therapeutic indications. We are delighted that he joins the executive management team at such a decisive stage of the company's development," said Dr. Guo-Liang Yu, CEO of Epitomics.

"RabMAb(R) is a novel class of monoclonal antibodies which possess unique biological properties, including ultra-high affinity, diversity in epitope recognition, and high target specificity. Epitomics provides me with the opportunity to expand the healthcare promises of biologics by developing RabMAb as a major therapeutic antibody discovery platform. We have embarked on a journey to bring truly widespread antibody therapy to patients around the world," said Dr. Zhiqiang An.

Prior to joining Epitomics, Dr. An played a major role in the creation of Merck's biologics research department including the establishment of their antibody technology platform. In his tenure at Merck, Dr. An and his team initiated a large number of antibody discovery programs in diverse therapeutics areas. As a result, multiple antibodies were identified as development candidates and are currently at various stages of development.

Dr. An started his biotech/pharmaceutical career at Millennium Pharmaceuticals where he established one of the very first programs attempting biocombinatorial natural products drug discovery using microbial molecular genetics and engineering approaches. Dr. An is a frequently invited speaker at scientific conferences and various academic settings and has authored numerous patents, journal articles, review papers, and books, including 2006's "Handbook of Industrial Mycology" and a comprehensive treatise entitled "Therapeutic Antibodies - from Theory to Practice," which will be published in early 2009. He received a B.S. in Biology from Shanxi Agricultural University, an M.S. in Biology from Beijing Agricultural University, and a Ph.D. in Plant Pathology from University of Kentucky, Lexington. Dr. An had his postdoctoral training at University of Wisconsin-Madison.

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb(R) (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc. (www.epitomics.com) is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
2. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
3. Codexis Appoints Singapore Laboratories Managing Director
4. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
5. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
6. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
9. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
10. NeurogesX Appoints New Director to the Board
11. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik ... Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... Foundation and administered by the New York Academy of Sciences to honor the ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
Breaking Biology News(10 mins):